Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain. The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC) and will be presented by Dr. Nilofer Azad, MD, FASCO, Professor of Oncology, Associate Director of Clinical Research, Sidney Kimmel Cancer Center at Johns Hopkins University. Presentation : Saturday, October 24, 2026 Session time : 10:15am – 11:45am CET Additional details regarding the presentation will be made available in accordance with ESMO Congress policies. About Compass Therapeutics Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets.